PMID- 11917058
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20190513
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 17
IP  - 4
DP  - 2002 Apr
TI  - Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular 
      disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
PG  - 637-44
AB  - BACKGROUND: Increased serum hepatocyte growth factor (HGF) level is a part of the 
      counter-system against tissue damage and predicts mortality in maintenance 
      haemodialysis (HD) patients. We studied which of the common co-morbid and 
      clinical conditions, and surrogates of metabolic disorders or specific organ 
      damage determine HGF levels in these subjects. METHODS: In 86 patients, 
      pre-dialysis serum HGF, soluble endothelial markers--such as thrombomodulin (TM), 
      von Willebrand factor and plasminogen activator inhibitor-1--and hepatitis B and 
      C markers were measured by ELISAs. Inflammatory reactants such as C-reactive 
      protein (CRP), alpha(1)-antitrypsin, alpha(1) acid-glycoprotein, and 
      immunoglobulin M and G were assayed by nephelometry, and lipoprotein(a) was 
      determined by ELISA. Cardiovascular disease (CVD) was identified on a clinical 
      basis. RESULTS: Serum HGF was directly associated with the presence of viral 
      hepatitis, alanine aminotransferase and TM levels, time on HD, the presence of 
      CVD, CRP and alpha(1)-antitrypsin levels, use of unfractionated heparin (UFH) (vs 
      enoxaparin) during HD, dose of UFH, use of recombinant erythropoietin (rHuEpo) 
      treatment, and Kt/V. In 36 patients not treated with rHuEpo, HGF directly 
      correlated with haemoglobin, but not with endogenous Epo levels. There was no 
      association between HGF and the other endothelial and inflammatory markers, 
      gender, age, smoking, cause of renal failure, body mass index, normalized protein 
      catabolic rate, dialysate buffers, dialysers, blood pressure, antihypertensive 
      treatment, leukocyte and platelet counts, albumin, fibrinogen, lipoprotein(a), 
      markers of iron and calcium-phosphorus metabolism, or metabolic acidosis. 
      Positive viral hepatitis markers, prevalent CVD and rHuEpo treatment (in 
      descending order of significance) were independent predictors of high HGF level. 
      In another 20 HD patients, a 4-week course of rHuEpo treatment resulted in a 
      significant 17% increase in circulating HGF levels. CONCLUSION: Serum HGF levels 
      in HD patients are determined by inflammatory conditions such as viral hepatitis 
      and CVD, increase in response to rHuEpo treatment, and may be influenced by type 
      and dose of heparin used during HD procedures.
FAU - Borawski, Jacek
AU  - Borawski J
AD  - Department of Nephrology and Internal Medicine, Medical Academy, Biakystok, 
      Poland. jborawsk@polbox.com
FAU - Mysliwiec, Michak
AU  - Mysliwiec M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Anticoagulants)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Cardiovascular Diseases/*blood
MH  - Erythropoietin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Hepatitis, Viral, Human/*blood
MH  - Hepatocyte Growth Factor/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins
MH  - *Renal Dialysis
EDAT- 2002/03/28 10:00
MHDA- 2002/08/16 10:01
CRDT- 2002/03/28 10:00
PHST- 2002/03/28 10:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2002/03/28 10:00 [entrez]
AID - 10.1093/ndt/17.4.637 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2002 Apr;17(4):637-44. doi: 10.1093/ndt/17.4.637.